NCT00596934View on ClinicalTrials.gov

Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Fatty Liver Disease, Nonalcoholic
Interventions
DRUG

metreleptin

0.1 mg/kg/day once a day via subcutaneous injections

Trial Locations (1)

48109

University of Michigan, Ann Arbor

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

University of Michigan

OTHER

lead

Elif Oral

OTHER

NCT00596934 - Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH) | Biotech Hunter | Biotech Hunter